# TINGSN

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tingsn

- Industry: Medical Devices & Equipment
- Headquarters: Suzhou, China
- Website: www.tingsn.com
- Total disclosed funding: $44M
- Latest round: Series B (Mar 5, 2026)
- Investors on record: 16

## About

Based in Suzhou, China and founded in 2019, Jiangsu Tingsn Technology Co., Ltd., trading as TINGSN, operates as a medical company that focuses on the production and sales of cardiac electrophysiological interventional devices. It has branch offices in Suzhou and Massachusetts, US. The company launched the development of 3D heart calibration systems. In March 2026, TINGSN closed Series B+ funding from Hunan Chasing Fund Management and Jinshan Capital.
The company is mainly engaged in the research and development of intracardiac ultrasound products. Its products include disposable intracardiac ultrasound catheters, portable color ultrasound diagnostic equipment, 4D intracardiac ultrasound imaging systems, and ultrasound three-dimensional mapping systems. Its three-dimensional cardiac mapping system can realize the real-time spatial positioning of interventional catheters. It also developed a PC-sided surgical simulator for VR virtual simulation operations.
The company generates revenue by doing R&D, and providing cardiac electrophysiology interventional devices and other related products.

## Funding rounds

- Series B, Mar 5, 2026 — Jinshan Capital, Hunan Chasing Fund Management
- Series B, Jun 25, 2025, $14M — Qiming Venture Partners, Efung Capital, Huangpu Biomedical Investment
- Series B, Jul 12, 2024 — Jingming Capital
- Series B, Sep 1, 2022, $15M — Qiming Venture Partners, Huatai Zijin Investment, Ascendum Capital, Tasly Capital Holdings Limited, Nanwan Baiao Fund
- Series A, Mar 3, 2022, $16M — Ti Capital Management, Origins Capital, Tao Capital, TigerYeah Capital, Huangpu Pharmaceutical Fund, Nuoyu Capital
- Angel, Dec 9, 2020 — Ti Capital Management

## Investors

- Ti Capital Management (https://capitalatlas.ai/funds/ti-capital-management) — Angel, Series A
- Origins Capital (https://capitalatlas.ai/funds/origins-capital) — Series A
- Tao Capital (https://capitalatlas.ai/funds/tao-capital) — Series A
- TigerYeah Capital (https://capitalatlas.ai/funds/tigeryeah-capital) — Series A
- Huangpu Pharmaceutical Fund — Series A
- Nuoyu Capital — Series A
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B
- Huatai Zijin Investment (https://capitalatlas.ai/funds/huatai-zijin-investment) — Series B
- Ascendum Capital (https://capitalatlas.ai/funds/ascendum-capital) — Series B
- Tasly Capital Holdings Limited (https://capitalatlas.ai/funds/tasly-capital-holdings-limited) — Series B
- Nanwan Baiao Fund — Series B
- Jingming Capital (https://capitalatlas.ai/funds/jingming-capital) — Series B
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series B
- Huangpu Biomedical Investment (https://capitalatlas.ai/funds/huangpu-biomedical-investment) — Series B
- Jinshan Capital (https://capitalatlas.ai/funds/jinshan-capital) — Series B
- Hunan Chasing Fund Management (https://capitalatlas.ai/funds/hunan-chasing-fund-management) — Series B